Scholarlink

<p>Human papillomavirus-induced cancers result from a synergy between genetic mutations and epigenetic reprogramming. The latter affects both the viral and host genomes, resulting in methylomic signatures, histone alterations and aberrant regulation of non-coding RNAs. These mechanisms contribute to tumor progression and provide new biomarkers for screening, risk stratification, and therapeutic monitoring. In a context where, despite vaccination campaigns, the incidence of HPV-positive cancers remains high particularly for oropharyngeal sites, the integration of these markers into precision medicine approaches appears essential. Future strategies will likely rely on a combination of vaccination, screening based on robust epigenetic panels, and the development of targeted epigenetic therapies, either alone or in combination with immunotherapy, to improve the prevention and management of HPV-associated cancers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Epigenetics and human papillomavirus-associated cancers: mechanisms, biomarkers, and clinical perspectives

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月2日

查看全文
  • Meriem Fassatoui,
  • Pascal Pineau,
  • Nicolas Berthet

摘要

Human papillomavirus-induced cancers result from a synergy between genetic mutations and epigenetic reprogramming. The latter affects both the viral and host genomes, resulting in methylomic signatures, histone alterations and aberrant regulation of non-coding RNAs. These mechanisms contribute to tumor progression and provide new biomarkers for screening, risk stratification, and therapeutic monitoring. In a context where, despite vaccination campaigns, the incidence of HPV-positive cancers remains high particularly for oropharyngeal sites, the integration of these markers into precision medicine approaches appears essential. Future strategies will likely rely on a combination of vaccination, screening based on robust epigenetic panels, and the development of targeted epigenetic therapies, either alone or in combination with immunotherapy, to improve the prevention and management of HPV-associated cancers.